Results 121 to 130 of about 72,405 (280)

Nail Psoriasis in Pediatric Populations

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Pediatric nail psoriasis is an under‐recognized yet clinically important manifestation of psoriasis with both diagnostic and prognostic implications. Nail involvement in children is associated with greater overall disease severity, poorer treatment outcomes, and is a predictor for the development of psoriatic arthritis.
Aditya K. Gupta   +3 more
wiley   +1 more source

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

open access: yesPLoS ONE
BackgroundThe Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV ...
Nimer S Alkhatib   +12 more
doaj   +1 more source

Neuritis óptica desmielinizante tras tratamiento con Infliximab [PDF]

open access: yes, 2007
Caso clínico: Se describe el caso de una paciente de 76 años de edad que presenta una disminución brusca de la agudeza visual en su ojo izquierdo. El cuadro es compatible con una neuritis óptica retrobulbar que en el contexto de una paciente de esta edad
Bidaguren,A.   +4 more
core  

Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense   +4 more
wiley   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease

open access: yes, 2018
Maochen Zhang,* Tianyu Zhang,* Liwen Hong, Chen Zhang, Jie Zhou, Rong Fan, Lei Wang, Zhengting Wang, Bin Xu, Jie Zhong Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic ...
Hong L   +9 more
core  

Severe malnutrition and persistent myopenia despite weight recovery in newly diagnosed stricturing Crohn's disease: A case report

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Protein‐energy malnutrition is a common complication in Crohn's disease (CD). In addition to weight loss, patients may develop significant alterations in body composition, including skeletal muscle depletion, which can negatively affect clinical outcomes and quality of life.
Beatriz Gabriela da Costa   +10 more
wiley   +1 more source

Designed Peptide Coacervates for Extracellular Antibody Targeting

open access: yesSmall, EarlyView.
Peptide‐based coacervates formed by liquid‐liquid phase separation provide a membraneless platform for therapeutic antibody delivery. Using Rituximab as a model, these coacervates enable efficient encapsulation, enhanced cell interactions, and provide partial protection from enzymatic proteolysis while maintaining low cytotoxicity.
Nofar Berman   +4 more
wiley   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada   +9 more
wiley   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Home - About - Disclaimer - Privacy